Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236

1.

Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?

Uematsu T, Kasami M, Watanabe J, Takahashi K, Yamasaki S, Tanaka K, Tadokoro Y, Ogiya A.

Breast Cancer. 2011 Oct;18(4):309-13. doi: 10.1007/s12282-010-0211-z. Epub 2010 Jun 24.

PMID:
20574730
2.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
3.

Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.

Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E.

Oncology. 2011;81(1):30-8. doi: 10.1159/000330766. Epub 2011 Sep 9.

PMID:
21912195
4.
5.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347
6.

MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?

McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G.

Ann Surg Oncol. 2011 Oct;18(11):3149-54. doi: 10.1245/s10434-011-1912-z. Epub 2011 Sep 27.

PMID:
21947592
7.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
8.

Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.

Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A.

Breast Cancer Res. 2001;3(3):183-91. Epub 2001 Feb 1.

9.
10.
11.

A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.

Miglietta L, Morabito F, Provinciali N, Canobbio L, Meszaros P, Naso C, Murialdo R, Boitano M, Salvi S, Ferrarini M.

Eur J Surg Oncol. 2013 Oct;39(10):1046-52. doi: 10.1016/j.ejso.2013.06.024. Epub 2013 Jul 26.

PMID:
23890870
12.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
13.

[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].

Wang LZ, Ouyang T, Wang TF, Xie YT, Fan ZQ, Fan T, Lin BY, Li JF.

Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):143-6. doi: 10.3760/cma.j.issn.0253-3766.2012.02.014. Chinese.

PMID:
22780935
14.

Presenting features of breast cancer differ by molecular subtype.

Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M.

Ann Surg Oncol. 2009 Oct;16(10):2705-10. doi: 10.1245/s10434-009-0606-2. Epub 2009 Jul 11.

PMID:
19593632
15.

[Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].

Yin HF, Wang YH, Qin XQ, Zhang H, Li T, Ye JM, Liu YH.

Zhonghua Zhong Liu Za Zhi. 2009 Nov;31(11):858-62. Chinese.

PMID:
20137353
16.

[Clinical characteristics and prognosis of breast cancer patients with vascular invasion].

Zhao WH, Xu BH, Zhang P, Li Q, Zhao LM, Sun Y.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):137-40. Chinese.

PMID:
17645853
17.

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.

J Clin Oncol. 2007 Oct 1;25(28):4423-30.

PMID:
17906205
19.

[Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].

Wang SY, Peng DF, Cai ZG, Zhang RZ, Yao TJ, Zhang H, Yang M, Dong HM.

Zhonghua Zhong Liu Za Zhi. 2008 Mar;30(3):203-6. Chinese.

PMID:
18756937
20.

Predictive factors for residual disease in re-excision specimens after breast-conserving surgery.

Atalay C, Irkkan C.

Breast J. 2012 Jul-Aug;18(4):339-44. doi: 10.1111/j.1524-4741.2012.01249.x. Epub 2012 May 23.

PMID:
22616572

Supplemental Content

Support Center